566 related articles for article (PubMed ID: 27015429)
1. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
2. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
3. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
4. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry.
Chiowchanwisawakit P; Katchamart W; Osiri M; Narongroeknawin P; Chevaisrakul P; Kitumnuaypong T; Siripaitoon B; Louthrenoo W
J Clin Rheumatol; 2019 Jan; 25(1):9-15. PubMed ID: 29517554
[TBL] [Abstract][Full Text] [Related]
8. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
9. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
10. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.
Fagerli KM; van der Heijde D; Heiberg MS; Wierød A; Kalstad S; Rødevand E; Mikkelsen K; Kvien TK; Lie E
Rheumatology (Oxford); 2014 Jun; 53(6):1087-94. PubMed ID: 24501243
[TBL] [Abstract][Full Text] [Related]
16. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
17. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
18. Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis.
Alazmi M; Sari I; Krishnan B; Inman RD; Haroon N
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1393-1399. PubMed ID: 29125891
[TBL] [Abstract][Full Text] [Related]
19. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
Ciurea A; Exer P; Weber U; Tamborrini G; Steininger B; Kissling RO; Bernhard J; Scherer A;
Arthritis Res Ther; 2016 Mar; 18():71. PubMed ID: 27000865
[TBL] [Abstract][Full Text] [Related]
20. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
